Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U.

Nat Med. 2017 Oct 6;23(10):1241. doi: 10.1038/nm1017-1241d.

PMID:
28985209
2.

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins.

Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, Diken M, Kreiter S, Türeci Ö, Sahin U.

Hum Gene Ther. 2017 Dec;28(12):1138-1146. doi: 10.1089/hum.2017.121. Epub 2017 Sep 6.

3.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö.

Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.

PMID:
28678784
4.

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U.

Nat Med. 2017 Jul;23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12. Erratum in: Nat Med. 2017 Oct 6;23 (10 ):1241.

PMID:
28604701
5.

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.

Diken M, Vormehr M, Grunwitz C, Kreiter S, Türeci Ö, Sahin U.

Methods Mol Biol. 2017;1499:223-236.

PMID:
27987153
6.

The European Regulatory Environment of RNA-Based Vaccines.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U.

Methods Mol Biol. 2017;1499:203-222. Review.

PMID:
27987152
7.

Past, present and future of immunology in Mainz.

Waisman A, Hövelmeyer N, Diefenbach A, Schuppan D, Reddehase MJ, Kleinert H, Kaina B, Grabbe S, Galle PR, Theobald M, Zipp F, Sahin U, Türeci Ö, Kreiter S, Langguth P, Decker H, van Zandbergen G, Schild H.

Cell Immunol. 2016 Oct;308:1-6. doi: 10.1016/j.cellimm.2016.09.001. No abstract available.

PMID:
27719802
8.

Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice.

Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, Diken M, Kreiter S.

Cancer Immunol Immunother. 2016 Sep;65(9):1075-83. doi: 10.1007/s00262-016-1869-7. Epub 2016 Jul 15.

PMID:
27422115
9.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U.

Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.

PMID:
27281205
10.

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.

Kreiter S, Diken M, Selmi A, Petschenka J, Türeci Ö, Sahin U.

Methods Mol Biol. 2016;1428:163-75. doi: 10.1007/978-1-4939-3625-0_11.

PMID:
27236799
11.

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.

Stadler CR, Bähr-Mahmud H, Plum LM, Schmoldt K, Kölsch AC, Türeci Ö, Sahin U.

Oncoimmunology. 2015 Oct 29;5(3):e1091555. eCollection 2016 Mar.

12.

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.

Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U.

Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509. Review.

13.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
14.

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.

Omokoko TA, Luxemburger U, Bardissi S, Simon P, Utsch M, Breitkreuz A, Türeci Ö, Sahin U.

J Immunol Res. 2016;2016:9540975. doi: 10.1155/2016/9540975. Epub 2016 Jan 5.

15.

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.

Vormehr M, Schrörs B, Boegel S, Löwer M, Türeci Ö, Sahin U.

J Immunol Res. 2015;2015:595363. doi: 10.1155/2015/595363. Epub 2015 Dec 30. Review.

16.

Mutanome directed cancer immunotherapy.

Vormehr M, Diken M, Boegel S, Kreiter S, Türeci Ö, Sahin U.

Curr Opin Immunol. 2016 Apr;39:14-22. doi: 10.1016/j.coi.2015.12.001. Epub 2015 Dec 21. Review.

PMID:
26716729
17.

Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors.

Wagner M, Jung J, Koslowski M, Türeci Ö, Tiwari VK, Sahin U.

Methods Mol Biol. 2016;1366:53-65. doi: 10.1007/978-1-4939-3127-9_6.

PMID:
26585127
18.

Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.

Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D, Türeci Ö, Yi K, Hamilton B, Sahin U.

Hum Gene Ther. 2015 Nov;26(11):751-66. doi: 10.1089/hum.2015.045. Epub 2015 Oct 1.

PMID:
26381596
19.

Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).

Kuemmel A, Simon P, Breitkreuz A, Röhlig J, Luxemburger U, Elsäßer A, Schmidt LH, Sebastian M, Sahin U, Türeci Ö, Buhl R.

Lung Cancer. 2015 Nov;90(2):334-41. doi: 10.1016/j.lungcan.2015.07.012. Epub 2015 Jul 30.

PMID:
26350112
20.

CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.

Paret C, Simon P, Vormbrock K, Bender C, Kölsch A, Breitkreuz A, Yildiz Ö, Omokoko T, Hubich-Rau S, Hartmann C, Häcker S, Wagner M, Roldan DB, Selmi A, Türeci Ö, Sahin U.

Oncotarget. 2015 Sep 22;6(28):25356-67. doi: 10.18632/oncotarget.4516.

21.

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

Omokoko T, Simon P, Türeci Ö, Sahin U.

Oncoimmunology. 2015 Mar 19;4(7):e1005523. eCollection 2015 Jul.

22.

Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Jul 16;523(7560):370. doi: 10.1038/nature14567. Epub 2015 Jun 3. No abstract available.

PMID:
26040715
23.

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Erratum in: Nature. 2015 Jul 16;523(7560):370.

24.

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.

Boisguérin V, Castle JC, Loewer M, Diekmann J, Mueller F, Britten CM, Kreiter S, Türeci Ö, Sahin U.

Br J Cancer. 2014 Oct 14;111(8):1469-75. doi: 10.1038/bjc.2013.820. Review.

25.

Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.

Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Türeci Ö, Sahin U.

Cancer Immunol Res. 2014 Dec;2(12):1230-44. doi: 10.1158/2326-6066.CIR-14-0108. Epub 2014 Sep 22.

26.

mRNA-based therapeutics--developing a new class of drugs.

Sahin U, Karikó K, Türeci Ö.

Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. Review.

PMID:
25233993
27.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.

Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O.

Cancer Immunol Immunother. 2014 Dec;63(12):1273-84. doi: 10.1007/s00262-014-1596-x. Epub 2014 Aug 28.

PMID:
25164876
28.

mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.

Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U.

Cancer Immunol Res. 2013 Dec;1(6):386-92. doi: 10.1158/2326-6066.CIR-13-0046. Epub 2013 Sep 20.

29.

Mutated tumor alleles are expressed according to their DNA frequency.

Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, de Graaf J, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

Sci Rep. 2014 Apr 22;4:4743. doi: 10.1038/srep04743.

30.

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.

Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.

31.

T-cell receptor transfer into human T cells with ecotropic retroviral vectors.

Koste L, Beissert T, Hoff H, Pretsch L, Türeci Ö, Sahin U.

Gene Ther. 2014 May;21(5):533-8. doi: 10.1038/gt.2014.25. Epub 2014 Apr 3.

PMID:
24694535
32.

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.

Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

BMC Genomics. 2014 Mar 13;15:190. doi: 10.1186/1471-2164-15-190.

33.

Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362.

Schnatbaum K, Schmoldt HU, Daneschdar M, Plum LM, Jansong J, Zerweck J, Kühne Y, Masch A, Wenschuh H, Fiedler M, Türeci Ö, Sahin U, Reimer U.

Biotechnol J. 2014 Apr;9(4):545-54. doi: 10.1002/biot.201300456. Epub 2014 Mar 7.

PMID:
24497417
34.

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells.

Wagner M, Koslowski M, Paret C, Schmidt M, Türeci O, Sahin U.

BMC Cancer. 2013 Dec 4;13:570. doi: 10.1186/1471-2407-13-570.

35.

Antigen identification using SEREX.

Sahin U, Türeci O.

Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3.

PMID:
23963930
36.

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.

Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci Ö.

Int J Cancer. 2014 Feb 1;134(3):731-9. doi: 10.1002/ijc.28400. Epub 2013 Sep 16.

37.

Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK.

Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, Schneider-Stock R, Klinger P, Greten FR, Threadgill DW, Sahin U, Neurath MF.

J Clin Invest. 2013 Apr;123(4):1428-43. doi: 10.1172/JCI63748. Epub 2013 Mar 15.

38.

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U.

Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Review.

PMID:
23296938
39.

HLA typing from RNA-Seq sequence reads.

Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, Türeci O, Diken M, Castle JC, Sahin U.

Genome Med. 2012 Dec 22;4(12):102. doi: 10.1186/gm403. eCollection 2012.

40.

Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity.

Bellinghausen I, Reuter S, Martin H, Maxeiner J, Luxemburger U, Türeci Ö, Grabbe S, Taube C, Saloga J.

J Allergy Clin Immunol. 2012 Dec;130(6):1384-93. doi: 10.1016/j.jaci.2012.08.039. Epub 2012 Oct 24.

PMID:
23102918
41.

Confidence-based somatic mutation evaluation and prioritization.

Löwer M, Renard BY, de Graaf J, Wagner M, Paret C, Kneip C, Türeci O, Diken M, Britten C, Kreiter S, Koslowski M, Castle JC, Sahin U.

PLoS Comput Biol. 2012;8(9):e1002714. doi: 10.1371/journal.pcbi.1002714. Epub 2012 Sep 27.

42.

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U.

Oncoimmunology. 2012 Aug 1;1(5):768-769.

43.

mRNA as a versatile tool for exogenous protein expression.

Kuhn AN, Beiβert T, Simon P, Vallazza B, Buck J, Davies BP, Tureci O, Sahin U.

Curr Gene Ther. 2012 Oct;12(5):347-61. Review.

PMID:
22827224
44.

Exploiting the mutanome for tumor vaccination.

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U.

Cancer Res. 2012 Mar 1;72(5):1081-91. doi: 10.1158/0008-5472.CAN-11-3722. Epub 2012 Jan 11.

45.

A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.

Reppert S, Boross I, Koslowski M, Türeci Ö, Koch S, Lehr HA, Finotto S.

Nat Commun. 2011 Dec 20;2:600. doi: 10.1038/ncomms1609.

PMID:
22186896
46.

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U.

Cancer Res. 2011 Oct 1;71(19):6132-42. doi: 10.1158/0008-5472.CAN-11-0291. Epub 2011 Aug 4.

47.

rapmad: Robust analysis of peptide microarray data.

Renard BY, Löwer M, Kühne Y, Reimer U, Rothermel A, Türeci O, Castle JC, Sahin U.

BMC Bioinformatics. 2011 Aug 4;12:324. doi: 10.1186/1471-2105-12-324.

48.

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals.

Türeci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U.

Gene. 2011 Aug 1;481(2):83-92. doi: 10.1016/j.gene.2011.04.007. Epub 2011 May 4.

PMID:
21571049
49.

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U.

Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Review.

PMID:
21497074
50.

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci Ö, Sahin U.

Gene Ther. 2011 Jul;18(7):702-8. doi: 10.1038/gt.2011.17. Epub 2011 Mar 3.

PMID:
21368901

Supplemental Content

Loading ...
Support Center